Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 · Cell · 5,288 citations
https://doi.org/10.1016/j.cell.2017.01.017
S
Siwen Hu‐Lieskovan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
291
Papers
24.7K
Citations
48
h-index
73
i10-index
Siwen Hu‐Lieskovan is an academic researcher from University of Utah. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Immunotherapy and Immune Responses. The author has an h-index of 48, co-authored 248 publications.
ORCID: 0000-0001-5836-4710Papers by this author
worksGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
2016 · Cell · 3,430 citations
https://doi.org/10.1016/j.cell.2016.02.065
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
2016 · New England Journal of Medicine · 3,062 citations
https://doi.org/10.1056/nejmoa1604958
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
2017 · Cell Reports · 1,821 citations
https://doi.org/10.1016/j.celrep.2017.04.031
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
2018 · Cancer Discovery · 534 citations
https://doi.org/10.1158/2159-8290.cd-17-1327
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
2020 · Nature Communications · 94 citations
https://doi.org/10.1038/s41467-019-12901-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat